JP7101684B2 - 一価の抗プロペルジン抗体および抗体断片 - Google Patents

一価の抗プロペルジン抗体および抗体断片 Download PDF

Info

Publication number
JP7101684B2
JP7101684B2 JP2019538396A JP2019538396A JP7101684B2 JP 7101684 B2 JP7101684 B2 JP 7101684B2 JP 2019538396 A JP2019538396 A JP 2019538396A JP 2019538396 A JP2019538396 A JP 2019538396A JP 7101684 B2 JP7101684 B2 JP 7101684B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
properdin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019538396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507561A (ja
JP2020507561A5 (OSRAM
Inventor
エル． シェリダン，ダグラス
ピー． タンブリーニ，ポール
アン－タナラ マック，タネーシャ
シー． ヴィエトリ，ウォルター
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020507561A publication Critical patent/JP2020507561A/ja
Publication of JP2020507561A5 publication Critical patent/JP2020507561A5/ja
Priority to JP2022107980A priority Critical patent/JP2022153405A/ja
Application granted granted Critical
Publication of JP7101684B2 publication Critical patent/JP7101684B2/ja
Priority to JP2024095141A priority patent/JP2024116321A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019538396A 2017-01-30 2018-01-30 一価の抗プロペルジン抗体および抗体断片 Active JP7101684B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022107980A JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片
JP2024095141A JP2024116321A (ja) 2017-01-30 2024-06-12 一価の抗プロペルジン抗体および抗体断片

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452187P 2017-01-30 2017-01-30
US62/452,187 2017-01-30
PCT/US2018/015985 WO2018140956A1 (en) 2017-01-30 2018-01-30 Monovalent anti-properdin antibodies and antibody fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022107980A Division JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片

Publications (3)

Publication Number Publication Date
JP2020507561A JP2020507561A (ja) 2020-03-12
JP2020507561A5 JP2020507561A5 (OSRAM) 2021-03-04
JP7101684B2 true JP7101684B2 (ja) 2022-07-15

Family

ID=62978808

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538396A Active JP7101684B2 (ja) 2017-01-30 2018-01-30 一価の抗プロペルジン抗体および抗体断片
JP2022107980A Pending JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片
JP2024095141A Pending JP2024116321A (ja) 2017-01-30 2024-06-12 一価の抗プロペルジン抗体および抗体断片

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022107980A Pending JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片
JP2024095141A Pending JP2024116321A (ja) 2017-01-30 2024-06-12 一価の抗プロペルジン抗体および抗体断片

Country Status (12)

Country Link
US (2) US11198725B2 (OSRAM)
EP (1) EP3573661A4 (OSRAM)
JP (3) JP7101684B2 (OSRAM)
KR (2) KR20230173731A (OSRAM)
CN (2) CN110831626B (OSRAM)
AU (2) AU2018212012B2 (OSRAM)
BR (1) BR112019014652A2 (OSRAM)
CA (1) CA3049806A1 (OSRAM)
CO (1) CO2019007686A2 (OSRAM)
IL (2) IL309890A (OSRAM)
MX (3) MX2019008827A (OSRAM)
WO (1) WO2018140956A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327188A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
US20220053741A1 (en) * 2018-09-13 2022-02-24 Regeneron Pharmaceuticals, Inc. Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
WO2021140475A1 (en) * 2020-01-08 2021-07-15 Cadila Healthcare Limited Anti-properdin antibodies and preparation thereof
JP7787164B2 (ja) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物
CN118593708A (zh) * 2020-10-30 2024-09-06 广州市妇女儿童医疗中心 诊断胆道闭锁的方法
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
EP4565608A2 (en) * 2022-08-05 2025-06-11 Alexion Pharmaceuticals, Inc. Pharmaceutical compositions of fusion proteins and methods of use thereof
TW202417490A (zh) * 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
CN118401253A (zh) * 2022-11-25 2024-07-26 领诺(上海)医药科技有限公司 备解素结合蛋白及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518636A (ja) 2004-11-03 2008-06-05 アムゲン・フレモント・インコーポレーテッド 抗プロペルジン抗体と、その作製方法および使用方法
JP2009514888A (ja) 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
JP2014522845A (ja) 2011-07-01 2014-09-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
JP2015503909A (ja) 2011-12-21 2015-02-05 ノバルティス アーゲー Ｐ因子を標的とする抗体のための組成物および方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
JP5735194B2 (ja) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2538114T3 (es) * 2008-03-03 2015-06-17 Novelmed Therapeutics, Inc. Anticuerpos anti-properdina
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
CA2811221C (en) 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
AU2012362217A1 (en) 2011-12-28 2014-07-24 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
JP2015532303A (ja) 2012-10-04 2015-11-09 ノベルメド セラピューティクス，インコーポレーテッド 溶血性疾患を治療するための補体第２経路特異的抗体
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518636A (ja) 2004-11-03 2008-06-05 アムゲン・フレモント・インコーポレーテッド 抗プロペルジン抗体と、その作製方法および使用方法
JP2009514888A (ja) 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
JP2014522845A (ja) 2011-07-01 2014-09-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
JP2015503909A (ja) 2011-12-21 2015-02-05 ノバルティス アーゲー Ｐ因子を標的とする抗体のための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tijink, B. M. et al.，Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology，Mol. Cancer Ther.，2008年，Vol. 7，pp. 2288-2297

Also Published As

Publication number Publication date
WO2018140956A1 (en) 2018-08-02
RU2019124873A3 (OSRAM) 2021-03-01
JP2024116321A (ja) 2024-08-27
IL267898B2 (en) 2024-06-01
KR20190111946A (ko) 2019-10-02
EP3573661A4 (en) 2020-08-12
CN118184777A (zh) 2024-06-14
CA3049806A1 (en) 2018-08-02
IL267898A (en) 2019-09-26
AU2018212012B2 (en) 2025-02-13
US20220162292A1 (en) 2022-05-26
MX2023004333A (es) 2023-05-04
MX2023007840A (es) 2023-07-07
CO2019007686A2 (es) 2019-07-31
RU2019124873A (ru) 2021-03-01
KR102613874B1 (ko) 2023-12-15
IL309890A (en) 2024-03-01
US20190352381A1 (en) 2019-11-21
CN110831626B (zh) 2024-04-19
EP3573661A1 (en) 2019-12-04
KR20230173731A (ko) 2023-12-27
IL267898B1 (en) 2024-02-01
BR112019014652A2 (pt) 2020-08-18
US12497445B2 (en) 2025-12-16
JP2022153405A (ja) 2022-10-12
CN110831626A (zh) 2020-02-21
MX2019008827A (es) 2019-09-26
AU2025200709A1 (en) 2025-02-20
JP2020507561A (ja) 2020-03-12
AU2018212012A1 (en) 2019-07-25
US11198725B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
JP7101684B2 (ja) 一価の抗プロペルジン抗体および抗体断片
US20250163138A1 (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
CN115667298A (zh) 自主凸起结构域肽
RU2790103C2 (ru) Моновалентные антитела к пропердину и фрагменты антител
HK40024594B (zh) 单价抗备解素抗体及抗体片段
HK40024594A (en) Monovalent anti-properdin antibodies and antibody fragments
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
WO2023034842A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
HK40089568A (zh) 新型癌症免疫治疗抗体组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190802

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220705

R150 Certificate of patent or registration of utility model

Ref document number: 7101684

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250